BioSpace News Archive

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2021 financial results on Tuesday, June 1, 2021 , after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results

Focused on robust expansion throughout Canada, the U.S. and Europe by way of strategic acquisitions and organic growth of services to existing patients.

-- Achieved $3.3 Million in Net Revenue in First Quarter -- -- Launched EYSUVIS® and Expanded Commercial Coverage to More than 69 Million Commercial Lives -- -- New Credit Facility Provides up to $125M -- -- Cash Runway Projected for at Least Two Years -- -- Conference Call and Webcast at 8:00 a.m. ET --

Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference

Q1 2021 revenue growth of 30.8% year-over-year, organic revenue growth of 23.8% Q1 2021 GAAP EPS of $0.37; non-GAAP EPS of $0.44, compared to $0.14 in Q1 2020 Raising fiscal year 2021 outlook on strong demand for the Company’s high-performance life science tools, scientific instruments and diagnostic solutions

First Quarter 2021 Procedure Volumes Increase 21.1% over First Quarter 2020 Cash and Cash Equivalents of $35.9 Million as of March 31, 2021

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, presented data on its 15-gene expression profile (15-GEP) test, DecisionDx®-UM, at the Association for Research in Vision and Ophthalmology (ARVO) 2021: Revolutionary Eye and Vision Research Meeting.

Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24 th Annual Meeting of the American Society of Gene & Cell Therapy TSHA-104 increased COX1 activity in brain and muscle and restored elevation of blood lactate on exhaustive exercise in dose-dependent manner in SURF1 knockout mice

-- First-Quarter 2021 Net Sales of $342.4 Million; First-Quarter 2021 GAAP Net Loss of $123.4 Million; Adjusted EBITDA of $45.8 Million -- -- First-Quarter 2021 Orphan Segment Net Sales Increased 5 Percent to $257.5 Million; KRYSTEXXA ® (pegloticase injection) First-Quarter 2021 Net Sales Increased 14 Percent to $106.7 Million --

First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Completed the acquisition of Trapelo Health in April